DIRIGO RESEARCH RECOMMENDS GeneLink BioSciences, Inc.
November 11, 2003

MARGATE, NJ - November 11, 2003 - GeneLink BioSciences, Inc. (OTCBB:GNLK) has recently been recommended by Dirigo Research of Camden, Maine. The two page report can be found on Dirigo website at www.DirigoResearch.com or on the GeneLink corporate website at www.genelink.info (PDF 82K)

In the Report, Dirigo's recommendation states that "Interest in GeneLink's patented process is growing dramatically by companies who manufacture and distribute nutrition supplements and skin care products, and we fully expect that a combination of the latest press releases and future announcements will bring heightened awareness to GeneLink's common shares - propelling them to much higher levels in coming months and seasons. We recommend purchase of GNLK for better than average capital appreciation."

Dirigo's recommendation also states "GeneLink continues to form alliances with some of the world's largest distributors of nutritional, skin care, personal care, wellness and anti-aging products for our benefit. People are not only interested in longevity - the quality of life is equally important, and both the healthcare and cosmetics industries address the way we look and feel. It is virtually impossible to find someone who is not interested in both looking and feeling younger, and with our own individual DNA available to makers and distributors of cosmetic and healthcare products, we can now experience both physical and emotional health to a degree which was previously unattainable. Still largely unnoticed by the investing public, GeneLink is well positioned for a glowing future. We expect both revenues and earnings to begin early in 2004. Trading at the midpoint of its 52-week price range, we believe that the company's common shares will move higher as investors begin to take notice of GeneLink, its technology, and its future potential."

About Dirigo Research: Dirigo Research has been a "publishing advisory service" since 1966. Since 1985, the firm has concentrated on low priced securities. Their stated goal is to report on six to eight "special situation" stocks a year in search of "really big winners" and report on them with "a fast reading, hard hitting, factual, up-to-the minute report. "The stocks we recommend Š move independently of the DJIA Š So we and our readers don't have to be concerned with hourly market swings", says Dirigo.

About GeneLink: GeneLink BioSciences, Inc. (www.genelink.info) since 1994, developed the World's First Family Centered DNA Bank and Hereditary Genetic Information Service. With recent breakthroughs, GeneLink is a pioneer and leading provider of DNA tests created to facilitate "genetically guided" health, beauty and wellness products. The company both markets and licenses its proprietary tests to the $1.4 trillion cosmetics, nutritional supplement and healthcare industries.

This press release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GNLK disclaims any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise.

SOURCE: GeneLink BioSciences, Inc.